Unlock instant, AI-driven research and patent intelligence for your innovation.

Stem cell preparation against hypoxia injury and its preparation method and use in preparation of medicine for treating acute myocardial infarction

A stem cell preparation and anti-hypoxia technology, applied in biochemical equipment and methods, animal cells, drug combinations, etc., can solve the problem of unclear transplanted cells

Active Publication Date: 2018-09-04
苍坤生物科技(上海)有限公司
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a marker of left ventricular remodeling in chronic systolic heart failure, Fstl1 can reduce pathological cardiac hypertrophy caused by pressure overload; however, whether Fstl1 can improve the ability of stem cells to resist hypoxic injury, thereby improving the residence of transplanted cells is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stem cell preparation against hypoxia injury and its preparation method and use in preparation of medicine for treating acute myocardial infarction
  • Stem cell preparation against hypoxia injury and its preparation method and use in preparation of medicine for treating acute myocardial infarction
  • Stem cell preparation against hypoxia injury and its preparation method and use in preparation of medicine for treating acute myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Preparation and Performance Testing of Anti-hypoxic Injury Stem Cell Preparation

[0034] The main materials and sources used are as follows:

[0035]C57BL / 6J mice (Zhaoyan New Drug Research Center, this experiment was approved by the ethics committee of Soochow University); DMEM / F12 medium (Gibco, USA); special medium for MSCs derived from mouse bone marrow (Saiye Biotech, China); pancreas Protease (Sigma, USA); ultra-clean bench (Antai, China); carbon dioxide incubator (Thermo, USA); desktop centrifuge (Thermo, USA); flow cytometer (Millipore, USA); inverted fluorescence microscope (ZEISS , Germany); Nanodrop2000 ultra-micro spectrophotometer (Thermo, USA); real-time fluorescent quantitative PCR instrument (ABI, USA); full-band multi-functional microplate reader (BIO-TEK, USA); reverse transcription kit (Takara, USA) Japan); FITC-CD29 antibody (Biolegend, USA); APC-CD44 antibody (Biolegend, USA); FITC-CD90 antibody (Biolegend, USA); PE-CD45 antibody (Bioleg...

Embodiment 2

[0059] Example 2 Anti-hypoxic injury stem cell preparation effectively improves cardiac function after myocardial infarction and has a better resident effect

[0060] The main materials and sources used are as follows:

[0061] C57BL / 6J mice (Zhaoyan New Drug Research Center, this experiment was approved by the Ethics Committee of Soochow University); small animal ventilator (Alcott Bio, Shanghai); surgical instruments (Liuliu Vision, Suzhou); suture needle and thread (Gold Huan Medical, Shanghai); small animal ultrasound imaging system (Visual Sonics Vevo 2100); inverted fluorescence microscope (ZEISS, Germany); Masson staining kit (Sigma, USA); mCherry antibody (Abcam, USA); FITC-labeled goat antibody Rabbit IgG secondary antibody (SentaCruz, USA); CM-DiI (Invitrogen, USA)

[0062]2.1 Establishment of myocardial infarction model in mice

[0063] About 25 g C57BL / 6J male mice were selected as the experimental subjects, and the left anterior descending coronary artery (left ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a stem cell preparation against hypoxia injury and its preparation method and use in preparation of a medicine for treating acute myocardial infarction. The preparation methodcomprises mixing stem cells and a Fstl1 over-expressed lentivirus liquid in a medium to obtain the stem cell preparation against hypoxia injury. The Fstl1-modified MSCs have excellent anti-hypoxia damage ability, can improve the transplant survival rate and can directly improve the heart function after infarction by direct injection into the heart muscle.

Description

technical field [0001] The invention belongs to cell medicine technology, and in particular relates to a stem cell preparation for resisting hypoxic damage, a preparation method thereof, and an application in preparation of medicine for treating acute myocardial infarction. Background technique [0002] Myocardial infarction is a cardiovascular disease that seriously endangers human health. With the continuous improvement of people's living standards in our country, the incidence of ischemic myocardial infarction is also increasing. Ischemic myocardial infarction leads to necrosis and scarring of cardiomyocytes, which in turn affects cardiac function. Most of the current drug or device treatments can only relieve the symptoms, but they cannot reverse the damage to the heart tissue. Although heart transplantation can completely improve the state of the heart, it is difficult to be widely used clinically due to factors such as scarcity of donor sources, immune rejection, and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0775A61K35/28A61P9/10
CPCA61K35/28A61P9/10C12N5/0663C12N2500/70
Inventor 陈维倩沈晗崔光浩沈振亚
Owner 苍坤生物科技(上海)有限公司